AYTU BIOPHARMA, INC Deferred Income Tax Expense (Benefit)
AYTU BIOPHARMA, INC (AYTU) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2024-09-26
- AYTU BIOPHARMA, INC deferred income tax expense (benefit) for the quarter ending 2016-06-30 was $0.00.
- AYTU BIOPHARMA, INC deferred income tax expense (benefit) for the quarter ending 2016-03-31 was $0.00.
- AYTU BIOPHARMA, INC deferred income tax expense (benefit) for the quarter ending 2015-12-31 was $0.00.
- AYTU BIOPHARMA, INC deferred income tax expense (benefit) for the quarter ending 2015-09-30 was $0.00.
- AYTU BIOPHARMA, INC deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- AYTU BIOPHARMA, INC deferred income tax expense (benefit) for fiscal 2023 was -$126.00K.
- AYTU BIOPHARMA, INC deferred income tax expense (benefit) for fiscal 2022 was -$117.00K, a 148.15% decline from fiscal 2021.
- AYTU BIOPHARMA, INC deferred income tax expense (benefit) for fiscal 2021 was $243.00K.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 10-K · filed 2024-09-26 | |||
| 2023-06-30 | -$126.00K 10-K · filed 2024-09-26 | |||
| 2022-06-30 | -$117.00K 10-K · filed 2023-10-12 | |||
| 2021-06-30 | $243.00K 10-K · filed 2022-09-27 | |||
| 2016-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-01 | $0.00 derived: sum of 2 quarters · filed 2016-09-01 | $0.00 derived: sum of 3 quarters · filed 2016-09-01 | $0.00 10-K · filed 2016-09-01 |
| 2016-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-11 | $0.00 derived: sum of 2 quarters · filed 2016-05-11 | $0.00 10-Q · filed 2016-05-11 | $0.00 derived: sum of 4 quarters · filed 2016-09-01 |
| 2015-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-11 | $0.00 10-Q · filed 2016-02-11 | $0.00 derived: sum of 3 quarters · filed 2016-09-01 | $0.00 derived: sum of 4 quarters · filed 2016-09-01 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-06 | $0.00 derived: sum of 2 quarters · filed 2016-09-01 | $0.00 derived: sum of 3 quarters · filed 2016-09-01 | -$1.00 derived: sum of 4 quarters · filed 2016-09-01 |
| 2015-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-01 | $0.00 derived: sum of 2 quarters · filed 2016-09-01 | -$1.00 derived: sum of 3 quarters · filed 2016-09-01 | -$23.91K 10-K · filed 2016-09-01 |
| 2015-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-11 | -$1.00 derived: sum of 2 quarters · filed 2016-05-11 | -$23.91K 10-Q · filed 2016-05-11 | -$288.45K derived: sum of 4 quarters · filed 2016-05-11 |
| 2014-12-31 | -$1.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-11 | -$23.91K 10-Q · filed 2016-02-11 | -$288.45K derived: sum of 3 quarters · filed 2016-02-11 | |
| 2014-09-30 | -$23.91K 10-Q · filed 2015-11-06 | -$288.45K derived: sum of 2 quarters · filed 2015-11-06 | ||
| 2014-06-30 | -$264.54K derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-28 | -$813.70K 10-K · filed 2015-09-28 | ||
| 2014-03-31 | -$549.16K 10-Q · filed 2015-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |